H5N1 Influenza Vaccine + H5N1 Influenza Vaccine
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prophylaxis of Avian Influenza
Conditions
Prophylaxis of Avian Influenza
Trial Timeline
Sep 1, 2007 → May 1, 2008
NCT ID
NCT00537524About H5N1 Influenza Vaccine + H5N1 Influenza Vaccine
H5N1 Influenza Vaccine + H5N1 Influenza Vaccine is a phase 2 stage product being developed by Novartis for Prophylaxis of Avian Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT00537524. Target conditions include Prophylaxis of Avian Influenza.
What happened to similar drugs?
2 of 13 similar drugs in Prophylaxis of Avian Influenza were approved
Approved (2) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00561184 | Phase 2 | Completed |
| NCT00537524 | Phase 2 | Completed |
Competing Products
20 competing products in Prophylaxis of Avian Influenza